Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours

Autor: Xinhui Chen, Nicolas Isambert, Rafael López‐López, Monica Giovannini, Nathalie Pognan, Shruti Kapoor, Michelle Quinlan, Benoit You, Xiaoming Cui, Gholamreza Rahmanzadeh, Morten Mau‐Sorensen

Publikováno v: Chen, X, Isambert, N, López-López, R, Giovannini, M, Pognan, N, Kapoor, S, Quinlan, M, You, B, Cui, X, Rahmanzadeh, G & Mau-Sorensen, M 2023, ' Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours ', British Journal of Clinical Pharmacology, vol. 89, no. 3, pp. 1046-1055 . https://doi.org/10.1111/bcp.15544

Background: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time-dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e751618123039bf7c0a8151dbb589a3e
https://curis.ku.dk/portal/da/publications/effect-of-capmatinib-on-the-pharmacokinetics-of-substrates-of-cyp3a-midazolam-and-cyp1a2-caffeine-in-patients-with-metdysregulated-solid-tumours(72512f3f-33d1-4b5e-974b-4b8e0ef1d394).html

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite

Autor: Regine Hansen, Yi Jin, Kirsten Schroer, Sylvia Zhao, Gian Camenisch, Hubert Borell, Gholamreza Rahmanzadeh, Jan Jaap van Lier, Axel Meissner, Ulrike Pfaar, Ulrike Glaenzel

Publikováno v: Drug Metabolism and Disposition. 48:873-885

Capmatinib (INC280), a highly selective and potent inhibitor of the MET receptor tyrosine kinase, has demonstrated clinically meaningful efficacy and a manageable safety profile in patients with advanced non-small-cell lung cancer harboring MET exon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b900aac9cb368b3fd41006b6a599782b
https://doi.org/10.1124/dmd.119.090324

Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study

Autor: Enrique, Grande, Monica, Giovannini, Eddie, Marriere, Philippe, Pultar, Michelle, Quinlan, Xinhui, Chen, Gholamreza, Rahmanzadeh, Giuseppe, Curigliano, Xiaoming, Cui

Publikováno v: British Journal of Clinical Pharmacology

Aims Capmatinib, an orally bioavailable, highly potent and selective MET inhibitor, was recently approved to treat adult patients with metastatic nonsmall cell lung cancer with METex14 skipping mutations. The study investigated the effect of capmatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::568979deb5b327206ec7558271064f54
https://pubmed.ncbi.nlm.nih.gov/33300203

Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3

Autor: Bharti Shah, Anton Drollmann, Cathy Gray, Erin Greco, Gholamreza Rahmanzadeh, Markus Weiss, Imad Hanna, Birk Poller, Swarupa Kulkarni

Publikováno v: Pulmonary Pharmacology & Therapeutics. 72:102097

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7ce33080e4bc530f17782af0d19b6ef
https://doi.org/10.1016/j.pupt.2021.102097